Carlo Bettocchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9342768/publications.pdf

Version: 2024-02-01

394286 395590 36 1,128 19 33 citations h-index g-index papers 36 36 36 1671 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget, 2015, 6, 13371-13386.	0.8	138
2	Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 397-407.	1.5	133
3	Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate, 2012, 72, 1611-1621.	1.2	83
4	Spondin-2, a Secreted Extracellular Matrix Protein, is a Novel Diagnostic Biomarker for Prostate Cancer. Journal of Urology, 2013, 190, 2271-2277.	0.2	67
5	Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1211-1224.	1.5	57
6	Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World Journal of Urology, 2015, 33, 1-7.	1.2	51
7	Soluble Serum αKlotho Is a Potential Predictive Marker of Disease Progression in Clear Cell Renal Cell Carcinoma. Medicine (United States), 2015, 94, e1917.	0.4	48
8	Diagnostic and Prognostic Role of Preoperative Circulating CA 15-3, CA 125, and Beta-2 Microglobulin in Renal Cell Carcinoma. Disease Markers, 2014, 2014, 1-9.	0.6	47
9	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell–Renal Cell Carcinoma. Medicine (United States), 2015, 94, e2117.	0.4	45
10	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. Expert Review of Molecular Diagnostics, 2019, 19, 377-387.	1.5	43
11	Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncology, 2013, 9, 899-907.	1.1	35
12	CTR2 Identifies a Population of Cancer Cells with Stem Cell-like Features in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 1831-1841.	0.2	35
13	Ejaculatory disorders: pathophysiology and management. Nature Reviews Urology, 2008, 5, 93-103.	1.4	34
14	Penile prostheses. Therapeutic Advances in Urology, 2010, 2, 35-40.	0.9	33
15	Erectile dysfunction and cardiovascular risk: a review of current findings. Expert Review of Cardiovascular Therapy, 2020, 18, 155-164.	0.6	33
16	Penile Prosthesis: What Should We Do about Complications?. Advances in Urology, 2008, 2008, 1-5.	0.6	28
17	Sildenafil: Efficacy and Safety in Daily Clinical Experience. European Urology, 2001, 40, 176-180.	0.9	24
18	Erectile dysfunction: symptom or disease?. Journal of Endocrinological Investigation, 2004, 27, 80-95.	1.8	23

#	Article	IF	CITATIONS
19	Clinical Recommendations From the European Society for Sexual Medicine Exploring Partner Expectations, Satisfaction in Male and Phalloplasty Cohorts, the Impact of Penile Length, Girth and Implant Type, Reservoir Placement, and the Influence of Comorbidities and Social Circumstances. Journal of Sexual Medicine, 2020, 17, 210-237.	0.3	21
20	Regulation of TGF- \hat{l}^21 expression by Androgen Deprivation Therapy of prostate cancer. Cancer Letters, 2012, 318, 135-144.	3.2	20
21	The effects of androgen depletion on human erectile function: a prospective study in male-to-female transsexuals. International Journal of Impotence Research, 2004, 16, 544-546.	1.0	19
22	Repair of Vaginal Prolapse following Penoscrotal Flap Vaginoplasty in a Male-to-Female Transsexual. Gynecologic and Obstetric Investigation, 2002, 53, 234-236.	0.7	18
23	Resistance Index as a Prognostic Factor for Prolonged Erection after Penile Dynamic Colour Doppler Ultrasonography. European Urology, 1998, 33, 94-97.	0.9	17
24	Tunica Albuginea Plication for the Correction of Penile Curvature. Scandinavian Journal of Urology and Nephrology, 2002, 36, 307-310.	1.4	15
25	Vasoactive intestinal polypeptide (VIP) is not an androgen-dependent neuromediator of penile erection. International Journal of Impotence Research, 2005, 17, 23-26.	1.0	15
26	Middle and Long-term Outcomes of Dual Kidney Transplant: A Multicenter Experience. Transplantation Proceedings, 2013, 45, 1237-1241.	0.3	15
27	Bilateral tumors of the testis in 21-alpha hydroxylase deficiency without adrenal hyperplasia. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 178-180.	0.8	12
28	Priapism After Transurethral Alprostadil. Journal of Urology, 1999, 161, 725-726.	0.2	5
29	Late-Onset Hypogonadism (LOH): Incidence, Diagnosis, and Short-Term Effects. European Urology Supplements, 2005, 4, 4-9.	0.1	4
30	Penile prosthesis implant for primary erectile dysfunction in patient with Klippel-Trenaunay syndrome complicated by consumptive coagulopathy. Medicine (United States), 2019, 98, e16741.	0.4	3
31	The Use of Penile Traction Devices for Peyronie's Disease: Position Statements from the European Society for Sexual Medicine. Sexual Medicine, 2021, 9, 100387.	0.9	3
32	GnRH in the Treatment of Hypogonadotropic Hypogonadism. Current Pharmaceutical Design, 2021, 27, 2754-2756.	0.9	2
33	Testicular cancer presenting as loss of vision. British Journal of Urology, 1995, 76, 519-520.	0.1	1
34	Management of severe complications following penile surgery for erectile dysfunction and Peyronie disease. Medicine (United States), 2020, 99, e18690.	0.4	1
35	The importance of biopsy in primary testicular failure. British Journal of Urology, 1995, 75, 105-106.	0.1	0
36	Penile Color Doppler Ultrasound in the Diagnosis of Erectile Dysfunction., 2017,, 551-558.		0